Global Archives – Page 4 of 25 – Treatment Action Group

New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN

September 20, 2023
Dorrit Walsh

As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens

September 19, 2023
Dorrit Walsh

Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Far Off Track: Funding for TB Research, 2018 – 2022

September 19, 2023
Dorrit Walsh

United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to…

Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%

August 16, 2023
Dorrit Walsh

In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.

TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus

August 2, 2023
Dorrit Walsh

Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

Employee Engagement Programs & Affinity Groups: Partner with TAG to Drive Social Impact

July 21, 2023
Dorrit Walsh

At Treatment Action Group (TAG), we recognize the immense potential of collective action in bringing about positive change. That's why we invite companies and organizations to join us in the fight against HIV, hepatitis C (HCV), and tuberculosis (TB) through…

Celebrate and Expand Your Support: Leverage the Power of Your Networks and Social Media

July 21, 2023
Dorrit Walsh

At Treatment Action Group (TAG), we believe in the power of social media to amplify support and spread awareness. By utilizing social media platforms and online communities, you can celebrate your special occasions while expanding your impact and raising awareness…

Join TAG’s Board: Shape the Future of Health Advocacy

July 21, 2023
Dorrit Walsh

Treatment Action Group (TAG) is seeking passionate individuals committed to ending the epidemics of HIV, hepatitis C (HCV), and tuberculosis (TB) to join our oard of directors. As a member of TAG's Board, you will play a pivotal role in…

Donor Advised Funds: Amplify Your Impact with Treatment Action Group

July 21, 2023
Dorrit Walsh

Supporting Treatment Action Group (TAG) through Donor Advised Funds (DAFs) empowers you to maximize the impact of your philanthropy. A Donor Advised Fund is a flexible giving vehicle that allows you to make a charitable contribution, receive an immediate tax…